Diagnostics and therapeutics for diseases associated with g-protein coupled protease activated receptor 1 (Par1)
AssigneeBayer HealthCare LLC
InventorsStefan Golz, Holger Summer
Life of this patent
Estimating the term…
Abstract
The invention provides a human PAR1 which is associated with the cardiovascular disorders, dermatological disorders, orders, gastrointestinal and liver diseases, neurological disorders, cancer disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, dermatological disorders, gastrointestinal and liver diseases, neurological disorders, cancer disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of PAR1 as well as pharmaceutical compositions comprising such compounds.
Claims15
A method of screening for therapeutic agents useful in the treatment of a disease selected from the group consisting of cardiovascular disorders, dermatological disorders, gastrointestinal and liver diseases, neurological disorders, cancer disorders and urological disorders in a mammal comprising the steps of
- i) contacting a test compound with a PAR1 polypeptide,
- ii) detecting binding of said test compound to said PAR1 polypeptide.
A method of screening for therapeutic agents useful in the treatment of a disease selected from the group consisting of cardiovascular disorders, dermatological disorders, gastrointestinal and liver diseases, neurological disorders, cancer disorders and urological disorders in a mammal comprising the steps of i) determining the activity of a PAR1 polypeptide at a certain concentration of a test compound or in the absence of said test compound, ii) determining the activity of said polypeptide at a different concentration of said test compound.
A method of screening for therapeutic agents useful in the treatment of a disease selected from the group consisting of cardiovascular disorders, dermatological disorders, gastrointestinal and liver diseases;
- neurological disorders, cancer disorders and urological disorders in a mammal comprising the steps of
- i) determining the activity of a PAR1 polypeptide at a certain concentration of a test compound,
- ii) determining the activity of a PAR1 polypeptide at the presence of a compound known to be a regulator of a PAR1 polypeptide.
4-11. (canceled)
A method of screening for therapeutic agents useful in the treatment of a disease selected from the group consisting of cardiovascular disorders, dermatological disorders, gastrointestinal and liver diseases, neurological disorders, cancer disorders and urological disorders in a mammal comprising the steps of
- i) contacting a test compound with a PAR1 polynucleotide,
- ii) detecting binding of said test compound to said PAR1 polynucleotide.
A method of diagnosing a disease selected from the group consisting of cardiovascular disorders, dermatological disorders, gastrointestinal and liver diseases, neurological disorders, cancer disorders and urological disorders in a mammal comprising the steps of
- i) determining the amount of a PAR1 polynucleotide in a sample taken from said mammal,
- ii) determining the amount of PAR1 polynucleotide in healthy and/or diseased mammals.
19-20. (canceled)
A pharmaceutical composition for the treatment of a disease selected from the group consisting of cardiovascular disorders, dermatological disorders, gastrointestinal and liver diseases, neurological disorders, cancer disorders and urological disorders in a mammal comprising a therapeutic agent which regulates the activity of a PAR1 polypeptide, wherein said therapeutic agent is
- i) a small molecule,
- ii) an RNA molecule,
- iii) an antisense oligonucleotide,
- iv) a polypeptide,
- v) an antibody, or
- vi) a ribozyme.
A pharmaceutical composition for the treatment of a disease selected from the group consisting of cardiovascular disorders, dermatological disorders, gastrointestinal and liver diseases, neurological disorders, cancer disorders and urological disorders in a mammal comprising a PAR1 polynucleotide or a PAR1 polypeptide.
23-26. (canceled)
Dependencies are inferred from the claim text.